Answers are grounded in this paper and cite their sources.
Explores limitations in TCR gene therapy due to fratricide in lymphocytes and toxicity in stem cells, suggesting the need for specific clinical applications.
The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated killing of hematopoietic stem cells. Specific clinical applications must therefore be conceived to bypass these limitations.
No takes yet. Share an insight, caveat, or question.
Schendel et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: